Notably, although these candidates vary in developmental stage and tumor type, they demonstrate synergistic effects when combined with PD-1/PD-L1 inhibitors, exhibiting superior antitumor activity compared to either agent alone (171). The gene discussed is PDCD1; the disease is neoplasm.